{
    "title": "Amgen says Lumakras cuts risk of lung cancer progression by 34%",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11202375/Amgen-says-Lumakras-cuts-risk-lung-cancer-progression-34.html",
    "date": "2022-09-11",
    "keywords": [
        "cancer",
        "lung",
        "chemotherapy",
        "amgen",
        "disease",
        "trial",
        "study",
        "drug",
        "company",
        "beasley",
        "pill",
        "difference",
        "survival",
        "approval",
        "meeting",
        "oncology",
        "esmo",
        "side",
        "form",
        "year",
        "lumakras",
        "risk",
        "progression",
        "sunday",
        "confirmatory",
        "condition",
        "month",
        "immunotherapy",
        "toxicity",
        "progressionfree",
        "length",
        "time",
        "monday",
        "society",
        "paris",
        "wall",
        "street",
        "yee",
        "benefit",
        "diarrhea",
        "medication",
        "gene",
        "nonsmall",
        "cell",
        "choice",
        "versus",
        "hospital",
        "head",
        "food",
        "administration",
        "pathway",
        "treatment",
        "agency",
        "dose",
        "sotorasib",
        "quarter",
        "fda",
        "decision",
        "adagrasib",
        "week",
        "combination",
        "reporting",
        "deena",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}